Results 11 to 20 of about 19,280 (221)

Contemporary management of pain in cirrhosis: Toward precision therapy for pain

Hepatology, EarlyView., 2022
Abstract Chronic pain is highly prevalent in patients with cirrhosis and is associated with poor health‐related quality of life and poor functional status. However, there is limited guidance on appropriate pain management in this population, and pharmacologic treatment can be harmful, leading to adverse outcomes, such as gastrointestinal bleeding ...
Alexis Holman, Neehar Parikh, Dan J. Clauw, David A. Williams, Elliot B. Tapper   +4 more
wiley   +1 more source

Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness

Hepatology, EarlyView., 2022
Abstract Background and Aims Reliable noninvasive biomarkers are an unmet clinical need for the diagnosis of NASH. This study investigates the diagnostic accuracy of the circulating triggering receptor expressed on myeloid cells 2 (plasma TREM2) as a biomarker for NASH in patients with NAFLD and elevated liver stiffness.
Vineesh Indira Chandran, Charlotte Wilhelmina Wernberg, Mette Munk Lauridsen, Maria Kløjgaard Skytthe, Sofie Marchsteiner Bendixen, Frederik Tibert Larsen, Camilla Dalby Hansen, Lea Ladegaard Grønkjær, Majken Storm Siersbæk, Tina Di Caterino, Sönke Detlefsen, Holger Jon Møller, Lars Grøntved, Kim Ravnskjaer, Søren Kragh Moestrup, Maja Sofie Thiele, Aleksander Krag, Jonas Heilskov Graversen   +17 more
wiley   +1 more source

Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS

Hepatology, EarlyView., 2022
The river diagram demonstrates that after transjugular intrahepatic portosystemic shunt insertion (TIPS) the majority of patients without ascites and 50% of the patients with ascites detectable at ultrasound, show the best response in the long term follow‐up.
Alexander Queck, Louise Schwierz, Wenyi Gu, Philip G. Ferstl, Christian Jansen, Frank E. Uschner, Michael Praktiknjo, Johannes Chang, Maximilian J. Brol, Filippo Schepis, Manuela Merli, Christian P. Strassburg, Jennifer Lehmann, Carsten Meyer, Jonel Trebicka   +14 more
wiley   +1 more source

Diagnostic and prognostic performance of urinary neutrophil gelatinase‐associated lipocalin in patients with cirrhosis and acute kidney injury

Hepatology, EarlyView., 2022
Diagnostic and prognostic ability of urinary NGAL in patients with cirrhosis and AKI. Abstract Background and Aims Acute kidney injury (AKI) commonly occurs in patients with decompensated cirrhosis. Urinary neutrophil gelatinase–associated lipocalin (uNGAL) could help discriminate between different etiologies of AKI.
Carmine Gambino, Salvatore Piano, Matteo Stenico, Marta Tonon, Alessandra Brocca, Valeria Calvino, Simone Incicco, Nicola Zeni, Roberta Gagliardi, Chiara Cosma, Martina Zaninotto, Patrizia Burra, Umberto Cillo, Daniela Basso, Paolo Angeli   +14 more
wiley   +1 more source

Factors associated with cardiovascular events after simultaneous liver–kidney transplant from the US Multicenter Simultaneous Liver–Kidney Transplant Consortium

Hepatology Communications, EarlyView., 2022
Abstract Cardiovascular disease is a leading complication after both liver and kidney transplantation. Factors associated with and rates of cardiovascular events (CVEs) after simultaneous liver–kidney transplant (SLKT) are unknown. This was a retrospective cohort study of adult SLKT recipients between 2002 and 2017 at six centers in six United Network ...
Jennifer Jo, Gonzalo Crespo, Dyanna Gregory, Jasmine Sinha, Jiaheng Xie, Min Zhang, John Magee, Pranab Barman, Yuval A. Patel, Aaron Schluger, Kara Walters, Scott Biggins, Natalia Filipek, Giuseppe Cullaro, Randi Wong, Jennifer C. Lai, Gabriel J. Perreault, Elizabeth C. Verna, Pratima Sharma, Lisa B. VanWagner   +19 more
wiley   +1 more source

TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update [PDF]

, 2010
Refractory ascites is a frequent complication of advanced cirrhosis and is associated with hepatorenal syndrome and hepatic hydrothorax. Large volume paracentesis and pleurodesis are regarded as first-line treatments in patients who do not respond ...
Gerbes, Alexander L., Roessle, Martin
core   +1 more source

Necessity and feasibility of developing diagnosis and treatment guidelines for  cirrhotic ascites and hepatorenal syndrome with Chinese intellectual property rights

Zhongguo linchuang yanjiu, 2023
At pressent, there are many controversies in China about the recommendations in Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome (hereinafter referred to as the “Guidelines”) revised in 2021 ...
LIU Jianjun, ZHENG Wenkai, GAO Tingting, WANG Jianghong, REN Yanjun, LIU Jianguo, LIU Changlin   +6 more
doaj   +1 more source

Interleukin-22 predicts severity and death in advanced liver cirrhosis: a prospective cohort study [PDF]

, 2012
Background: Interleukin-22 (IL-22), recently identified as a crucial parameter of pathology in experimental liver damage, may determine survival in clinical end-stage liver disease.
Bachmann, Malte, Brunner, Friederike, Filmann, Natalie, Herrmann, Eva, Kapper, Lisa, Kronenberger, Bernd, Mühl, Heiko, Pfeilschifter, Josef Martin (Prof. Dr.), Piiper, Albrecht, Rudloff, Ina, Waidmann, Oliver, Zeuzem, Stefan   +11 more
core   +1 more source

Kidney failure due to liver cirrhosis – hepatorenal syndrome: Clinical case [PDF]

BIO Web of Conferences
These days, kidney failure is a big problem globally and can even lead to death for patients. There are many things that can cause kidneys to stop working properly, and liver diseases are especially important.
Jumayeva Madina, Ubaydova Dilafruz, Xayrullayeva Gulrux, Kadirova Zarina, Ergashov Bobur, Narzullayeva Dildora   +5 more
doaj   +1 more source

Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies [PDF]

, 2017
Background The goal of hepatorenal syndrome type 1 (HRS-1) treatment is to improve renal function. Terlipressin, a synthetic vasopressin analogue, is a systemic vasoconstrictor used for the treatment of HRS-1, where it is available.
Araya, V., Boyer, T. D., Escalante, S., Frederick, R. T., Jamil, K., Pappas, S. C., Reddy, K. R., Rossaro, L., Sanyal, A. J., Teuber, P., Vargas, H. E., Wong, F.   +11 more
core   +2 more sources